Matchpoint Therapeutics Inc. has synthesized new diazepino-thieno-quinoxaline compounds acting as MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2) inhibitors reported to be useful for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback